Pendal Group Ltd purchased a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,973 shares of the biopharmaceutical company’s stock, valued at approximately $1,244,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Westpac Banking Corp boosted its position in shares of Regeneron Pharmaceuticals by 60.8% in the 2nd quarter. Westpac Banking Corp now owns 8,948 shares of the biopharmaceutical company’s stock valued at $2,801,000 after purchasing an additional 3,383 shares during the period. Cibc Bank USA acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $448,000. Stevens Capital Management LP lifted its stake in shares of Regeneron Pharmaceuticals by 4,383.7% during the second quarter. Stevens Capital Management LP now owns 32,238 shares of the biopharmaceutical company’s stock worth $10,090,000 after purchasing an additional 31,519 shares in the last quarter. Sector Gamma AS acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $18,040,000. Finally, CWM LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2,254.5% during the second quarter. CWM LLC now owns 518 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 496 shares in the last quarter. Institutional investors own 66.97% of the company’s stock.
Regeneron Pharmaceuticals stock traded up $0.89 during midday trading on Friday, hitting $294.00. The stock had a trading volume of 9,957 shares, compared to its average volume of 730,896. The company has a current ratio of 3.88, a quick ratio of 3.11 and a debt-to-equity ratio of 0.07. The stock has a market cap of $31.94 billion, a P/E ratio of 14.74, a P/E/G ratio of 1.39 and a beta of 1.15. Regeneron Pharmaceuticals Inc has a 12 month low of $287.66 and a 12 month high of $442.00. The business has a fifty day moving average price of $304.45 and a 200 day moving average price of $350.82.
A number of research analysts have commented on the company. UBS Group reduced their price objective on Regeneron Pharmaceuticals from $480.00 to $440.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th. BidaskClub upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, July 19th. Cantor Fitzgerald reduced their price objective on Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating on the stock in a research note on Monday, May 13th. Finally, TheStreet cut Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Wednesday, June 5th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average price target of $398.25.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.